| First Author | Guo A | Year | 2022 |
| Journal | Nature | Volume | 607 |
| Issue | 7917 | Pages | 135-141 |
| PubMed ID | 35732731 | Mgi Jnum | J:330915 |
| Mgi Id | MGI:7367321 | Doi | 10.1038/s41586-022-04849-0 |
| Citation | Guo A, et al. (2022) cBAF complex components and MYC cooperate early in CD8(+) T cell fate. Nature 607(7917):135-141 |
| abstractText | The identification of mechanisms to promote memory T (Tmem) cells has important implications for vaccination and anti-cancer immunotherapy(1-4). Using a CRISPR-based screen for negative regulators of Tmem cell generation in vivo(5), here we identify multiple components of the mammalian canonical BRG1/BRM-associated factor (cBAF)(6,7). Several components of the cBAF complex are essential for the differentiation of activated CD8(+) T cells into T effector (Teff) cells, and their loss promotes Tmem cell formation in vivo. During the first division of activated CD8(+) T cells, cBAF and MYC(8) frequently co-assort asymmetrically to the two daughter cells. Daughter cells with high MYC and high cBAF display a cell fate trajectory towards Teff cells, whereas those with low MYC and low cBAF preferentially differentiate towards Tmem cells. The cBAF complex and MYC physically interact to establish the chromatin landscape in activated CD8(+) T cells. Treatment of naive CD8(+) T cells with a putative cBAF inhibitor during the first 48 h of activation, before the generation of chimeric antigen receptor T (CAR-T) cells, markedly improves efficacy in a mouse solid tumour model. Our results establish cBAF as a negative determinant of Tmem cell fate and suggest that manipulation of cBAF early in T cell differentiation can improve cancer immunotherapy. |
